Modus Therapeutics Holding Past Earnings Performance
Past criteria checks 0/6
Modus Therapeutics Holding has been growing earnings at an average annual rate of 16.4%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
16.4%
Earnings growth rate
-14.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -101.2% |
| Net Margin | n/a |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Modus Therapeutics Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -18 | 8 | 8 |
| 30 Sep 23 | 0 | -23 | 7 | 15 |
| 30 Jun 23 | 0 | -23 | 7 | 15 |
| 31 Mar 23 | 0 | -21 | 7 | 14 |
| 31 Dec 22 | 0 | -18 | 7 | 11 |
| 30 Sep 22 | 0 | -21 | 7 | 14 |
| 30 Jun 22 | 0 | -23 | 8 | 15 |
| 31 Mar 22 | 0 | -22 | 8 | 14 |
| 31 Dec 21 | 0 | -21 | 7 | 14 |
| 30 Sep 21 | 0 | -9 | 6 | 4 |
| 30 Jun 21 | 0 | -6 | 4 | 2 |
| 31 Mar 21 | 0 | -5 | 2 | 3 |
| 31 Dec 20 | 0 | -6 | 2 | 4 |
| 31 Dec 19 | 0 | -44 | 7 | 36 |
Quality Earnings: MODTX is currently unprofitable.
Growing Profit Margin: MODTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MODTX is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare MODTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MODTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: MODTX has a negative Return on Equity (-101.22%), as it is currently unprofitable.